CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
human retinal progenitor cells +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03073733
NCT03073733Phase 2Completed
CompareCT.gov

A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)

jCyte, Inc·interventional·Posted Mar 8, 2017·Updated Jun 18, 2024

In Brief

A Phase 2 clinical trial evaluating human retinal progenitor cells and Mock injection for Retinitis Pigmentosa. Completed, enrolled 84 participants across 3 sites.

Detailed Summary

This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinitis Pigmentosa
CountriesUnited States
CollaboratorsCalifornia Institute for Regenerative Medicine (CIRM)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 8, 2017
Enrollment StartMar 1, 2017
Primary CompletionNov 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.3 years ago

Interventions

human retinal progenitor cellsbiological

live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia

Mock injectionother

pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection